Soluble Guanylate Cyclase Activators for Glaucoma Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma and ocular hypertension often have adverse effects and do not effectively enhance aqueous humor drainage, leading to incomplete reduction of intraocular pressure (IOP).
Innovation Solution
Development of 2-pyridine piperidine carboxylic acid compounds that activate soluble guanylate cyclase (sGC), which increase aqueous humor outflow, thereby reducing IOP, specifically targeting the trabecular outflow pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stress or pressure
If prostaglandin analogs are used to decrease IOP by increasing aqueous outflow, then IOP reduction is achieved, but undesirable effects such as increased conjunctival hyperaemia and iris hyperpigmentation occur
Solution Approach 1:
The patent changes the pharmacological mechanism from prostaglandin receptor activation to soluble guanylate cyclase activation. This parameter change in the molecular target leads to a different downstream signaling pathway (increased cGMP) that achieves IOP reduction without the adverse effects associated with prostaglandin analogs, such as conjunctival hyperaemia and iris hyperpigmentation
Solution Approach 2:
The patent introduces soluble guanylate cyclase and cyclic GMP as intermediary molecules in the IOP reduction pathway. Instead of directly activating prostaglandin receptors, the compounds activate sGC to produce cGMP, which then mediates the IOP-lowering effect through a different cellular mechanism that avoids the harmful side effects
2Stress or pressure
If parasympathomimetics are used to decrease IOP, then IOP reduction is achieved, but accommodative changes leading to blurring of vision occur
Solution Approach 1:
The patent changes the mechanism from parasympathomimetic activation of muscarinic receptors to soluble guanylate cyclase activation. This parameter change shifts the pharmacological action from direct smooth muscle contraction (causing accommodative changes) to a cGMP-mediated pathway that reduces IOP without affecting accommodation
3Stress or pressure
If sympathomimetics are used to increase aqueous outflow, then IOP reduction is partially achieved, but aqueous humor production is stimulated which counteracts the outflow effect
Solution Approach 1:
The patent changes the mechanism from sympathomimetic activation of adrenergic receptors to soluble guanylate cyclase activation. This parameter change eliminates the dual effect of sympathomimetics (increasing both outflow and production) by targeting a pathway that specifically enhances outflow through cGMP-mediated relaxation of outflow pathway structures without stimulating production
4Stress or pressure
If beta-blockers or carbonic anhydrase inhibitors are used to reduce aqueous humor production, then IOP is decreased, but the mechanism does not directly address outflow obstruction
Solution Approach 1:
The patent changes the mechanism from reducing aqueous humor production to directly enhancing aqueous humor outflow through soluble guanylate cyclase activation. This parameter change addresses the primary pathophysiology of glaucoma (outflow obstruction) rather than compensating by reducing production, providing a more direct and reliable treatment approach
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively reduce IOP by enhancing aqueous humor drainage, providing a potential treatment for glaucoma and ocular hypertension with a reduced adverse event profile compared to existing therapies.
Implementation Method 1
2-pyridine piperidine carboxylic acid compounds that activate soluble guanylate cyclase (sGC), which increase aqueous humor outflow, thereby reducing IOP
Data Source
AI summary
The invention relates to activators of soluble guanylate cyclase and their use in pharmaceutical compositions, primarily topically administered ophthalmic compositions. The pharmaceutical compositions are useful for reducing intraocular pressure in animals of the mammalian species.